CPO-107 clinical trials
Also written JMT601.
How each study uses CPO-107 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the CPO-107 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2021 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Shanghai JMT-Bio Inc. (2) · Conjupro Biotherapeutics, Inc. (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test CPO-107.
- Apr 2027A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous NephropathyPhase 2 · Shanghai JMT-Bio Inc.
Studies
Open first, then newest update. How each study uses CPO-107 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous NephropathyNot yet recruitingPhase 2Shanghai JMT-Bio Inc.NCT07029139Written as JMT601 Injection
- A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin LymphomaRecruitingPhase 1Shanghai JMT-Bio Inc.NCT06725524Written as JMT601
- Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins LymphomaTerminatedPhase 1Conjupro Biotherapeutics, Inc.NCT04853329Written as CPO107
Codes
What other systems call CPO-107 · ClinicalTrials.gg INT015202
- UNII (FDA) 65RC2F9XABCPO-107One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 65RC2F9XAB | CPO-107 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.